{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T20:43:48Z","timestamp":1762548228048,"version":"build-2065373602"},"reference-count":156,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T00:00:00Z","timestamp":1747958400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018987","name":"Romanian Government Ministry of Research and Innovation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018987","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015622","name":"Ministerul Cercet\u0103rii \u015fi Inov\u0103rii","doi-asserted-by":"publisher","award":["PNRR\/2022\/C9\/MCID\/18","760278\/March 26","PNRR 2024\\u20132026"],"award-info":[{"award-number":["PNRR\/2022\/C9\/MCID\/18","760278\/March 26","PNRR 2024\\u20132026"]}],"id":[{"id":"10.13039\/501100015622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018693","name":"Horizon Europe","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018693","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Haematology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.beha.2025.101637","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T19:28:28Z","timestamp":1747942108000},"page":"101637","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Adoptive cellular therapies in non-Hodgkin lymphomas"],"prefix":"10.1016","volume":"38","author":[{"given":"David","family":"Kegyes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bogdan","family":"Borlea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Damian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian Bogdan","family":"Tigu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madalina","family":"Nistor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Cenariu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raluca","family":"Munteanu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Gulei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Dascalescu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ion","family":"Antohe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alina","family":"Tanase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anca","family":"Colita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nazar","family":"Shokun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetiana","family":"Skrypets","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Federico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ciprian","family":"Tomuleasa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.beha.2025.101637_bib1","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"year":"2024","series-title":"Global cancer observatory: cancer today","author":"Ferlay","key":"10.1016\/j.beha.2025.101637_bib2"},{"issue":"1","key":"10.1016\/j.beha.2025.101637_bib3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/ejh.13863","article-title":"The diagnosis and management of suspected lymphoma in general practice","volume":"110","author":"Paquin","year":"2023","journal-title":"Eur J Haematol"},{"issue":"5","key":"10.1016\/j.beha.2025.101637_bib4","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/ajh.26151","article-title":"Update on Diffuse large B cell lymphoma: a review of current data and potential applications on risk stratification and management","volume":"96","author":"Susanibar\u2010Adaniya","year":"2021","journal-title":"Am J Hematol"},{"issue":"12","key":"10.1016\/j.beha.2025.101637_bib5","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1002\/ajh.27470","article-title":"Hodgkin lymphoma: 2025 update on diagnosis, risk\u2010stratification, and management","volume":"99","author":"Ansell","year":"2024","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.beha.2025.101637_bib6","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1111\/bjh.19295","article-title":"New standards of care for treatment of diffuse large B\u2010cell lymphoma","volume":"204","author":"Abeyakoon","year":"2024","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2025.101637_bib7","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2147\/JBM.S190784","article-title":"How the discovery of rituximab impacted the treatment of B-cell non-Hodgkin\u2019s lymphomas","volume":"10","author":"Mohammed","year":"2019","journal-title":"JBM"},{"issue":"10","key":"10.1016\/j.beha.2025.101637_bib8","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1002\/ajh.27058","article-title":"Marginal zone lymphoma: 2023 update on diagnosis and management","volume":"98","author":"Cheah","year":"2023","journal-title":"Am J Hematol"},{"issue":"7","key":"10.1016\/j.beha.2025.101637_bib9","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.3390\/cancers16071285","article-title":"Comparing R-bendamustine vs. R-CHOP plus maintenance therapy as first-line systemic treatment in follicular lymphoma: a multicenter retrospective GELTAMO study","volume":"16","author":"Bastos-Oreiro","year":"2024","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.beha.2025.101637_bib10","doi-asserted-by":"crossref","first-page":"977","DOI":"10.3390\/biomedicines12050977","article-title":"Beyond chemotherapy: present and future perspectives in the treatment of lymphoproliferative disorders","volume":"12","author":"Massaro","year":"2024","journal-title":"Biomedicines"},{"issue":"2","key":"10.1016\/j.beha.2025.101637_bib11","doi-asserted-by":"crossref","first-page":"108","DOI":"10.6004\/jnccn.2023.0007","article-title":"NCCN Guidelines\u00ae insights: hematopoietic cell transplantation, version 3.2022: featured updates to the NCCN guidelines","volume":"21","author":"Saad","year":"2023","journal-title":"J Natl Compr Cancer Netw"},{"issue":"3","key":"10.1016\/j.beha.2025.101637_bib12","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41568-020-00323-z","article-title":"Recent advances and discoveries in the mechanisms and functions of CAR T cells","volume":"21","author":"Larson","year":"2021","journal-title":"Nat Rev Cancer"},{"issue":"10","key":"10.1016\/j.beha.2025.101637_bib13","doi-asserted-by":"crossref","DOI":"10.1038\/nrd.2017.196","article-title":"FDA approves first CAR T therapy","volume":"16","author":"Mullard","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.beha.2025.101637_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1188049","article-title":"From bench to bedside: the history and progress of CAR T cell therapy","volume":"14","author":"Mitra","year":"2023","journal-title":"Front Immunol"},{"issue":"11","key":"10.1016\/j.beha.2025.101637_bib15","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1182\/bloodadvances.2024013656","article-title":"Impact of vein-to-vein time in patients with R\/R LBCL treated with axicabtagene ciloleucel","volume":"9","author":"Locke","year":"2025","journal-title":"Blood Adv"},{"issue":"19","key":"10.1016\/j.beha.2025.101637_bib16","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1182\/bloodadvances.2020002394","article-title":"Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Locke","year":"2020","journal-title":"Blood Adv"},{"issue":"24","key":"10.1016\/j.beha.2025.101637_bib17","doi-asserted-by":"crossref","first-page":"5976","DOI":"10.1111\/jcmm.17550","article-title":"Predictors of response to axicabtagene\u2010ciloleucel CAR T cells in aggressive B cell lymphomas: a real\u2010world study","volume":"26","author":"Iovino","year":"2022","journal-title":"J Cell Mol Med"},{"issue":"27","key":"10.1016\/j.beha.2025.101637_bib18","first-page":"3119","article-title":"Standard-of-Care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US lymphoma CAR T consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J Clin Orthod"},{"issue":"1","key":"10.1016\/j.beha.2025.101637_bib19","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.beha.2025.101637_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1517348","article-title":"Outcomes with bridging radiation therapy prior to chimeric antigen receptor T-cell therapy in patients with aggressive large B-cell lymphomas","volume":"16","author":"Manzar","year":"2025","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.beha.2025.101637_bib21","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.3390\/cancers15061747","article-title":"Long-term follow-up of bridging therapies prior to CAR T-cell therapy for relapsed\/refractory large B cell lymphoma","volume":"15","author":"Ladbury","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.beha.2025.101637_bib22","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2025015855","article-title":"Bridging radiotherapy prior to chimeric antigen receptor T-cells for B-cell lymphomas: an ILROG multicenter study","author":"Yegya-Raman","year":"2025","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.beha.2025.101637_bib23","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1182\/bloodadvances.2023011489","article-title":"Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: results from the US Lymphoma CAR-T Consortium","volume":"8","author":"Jain","year":"2024","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.beha.2025.101637_bib24","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.62347\/LLXR8002","article-title":"Impact of debulking therapy on the clinical outcomes of axicabtagene ciloleucel in the treatment of relapsed or refractory large B-cell lymphoma","volume":"14","author":"Van Meerten","year":"2024","journal-title":"Am J Cancer Res"},{"issue":"12","key":"10.1016\/j.beha.2025.101637_bib25","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1182\/bloodadvances.2022009019","article-title":"Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma","volume":"7","author":"Roddie","year":"2023","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.beha.2025.101637_bib26","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/j.jtct.2023.12.049","article-title":"Acalabrutinib in combination with anti-CD19 chimeric antigen receptor T-cell therapy in relapsed\/refractory B-cell lymphoma: a phase I\/II study of safety, efficacy and immune correlative analysis","volume":"30","author":"Poh","year":"2024","journal-title":"Transplant Cell Therapy"},{"issue":"13","key":"10.1016\/j.beha.2025.101637_bib27","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1182\/bloodadvances.2022008294","article-title":"Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy","volume":"7","author":"Wudhikarn","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.beha.2025.101637_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1403145","article-title":"Comparing 2-day vs 3-day flu-CY lymphodepleting regimens for CD19 CAR T-cell therapy in patients with non-hodgkin\u2019s lymphoma","volume":"15","author":"Frame","year":"2024","journal-title":"Front Immunol"},{"issue":"18","key":"10.1016\/j.beha.2025.101637_bib29","doi-asserted-by":"crossref","first-page":"5579","DOI":"10.1182\/bloodadvances.2023010302","article-title":"Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma","volume":"7","author":"Scordo","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.beha.2025.101637_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2025.03.012","article-title":"Comparative efficacy of bendamustine versus fludarabine\/cyclophosphamide for lymphodepletion before chimeric antigen receptor T-cell therapy in lymphoma","author":"Rao","year":"2025","journal-title":"Transplant Cell Therapy"},{"issue":"1","key":"10.1016\/j.beha.2025.101637_bib31","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13045-024-01542-9","article-title":"Efficacy and safety of bendamustine for lymphodepletion before lisocabtagene maraleucel","volume":"17","author":"Ghilardi","year":"2024","journal-title":"J Hematol Oncol"},{"issue":"11","key":"10.1016\/j.beha.2025.101637_bib32","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/ajh.27069","article-title":"Bendamustine lymphodepletion is a well\u2010tolerated alternative to fludarabine and cyclophosphamide lymphodepletion for axicabtagene ciloleucel therapy for aggressive B\u2010cell lymphoma","volume":"98","author":"Ong","year":"2023","journal-title":"Am J Hematol"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2025.101637_bib33","doi-asserted-by":"crossref","first-page":"10380","DOI":"10.1182\/blood-2022-156120","article-title":"3-Year follow-up analysis of ZUMA-5: a phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients with relapsed\/refractory (R\/R) indolent non-hodgkin lymphoma (iNHL)","volume":"140","author":"Neelapu","year":"2022","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.beha.2025.101637_bib34","doi-asserted-by":"crossref","first-page":"726.e1","DOI":"10.1016\/j.jtct.2024.03.015","article-title":"Bendamustine as lymphodepletion for brexucabtagene autoleucel therapy of mantle cell lymphoma","volume":"30","author":"Chong","year":"2024","journal-title":"Transplant Cell Therapy"},{"issue":"5","key":"10.1016\/j.beha.2025.101637_bib35","first-page":"1460","article-title":"Effect of delayed cell infusion in patients with large B-cell lymphoma treated with chimeric antigen receptor T-cell therapy","volume":"109","author":"Jallouk","year":"2024","journal-title":"Haematologica."},{"issue":"26","key":"10.1016\/j.beha.2025.101637_bib36","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.beha.2025.101637_bib37","first-page":"2307","article-title":"5-Year follow-up supports curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1)","volume":"141","author":"Neelapu","year":"2023","journal-title":"Blood"},{"issue":"30","key":"10.1016\/j.beha.2025.101637_bib38","first-page":"3581","article-title":"Five-year follow-up of standard-of-care axicabtagene ciloleucel for large B-cell lymphoma: results from the US lymphoma CAR T consortium","volume":"42","author":"Jain","year":"2024","journal-title":"J Clin Orthod"},{"issue":"7","key":"10.1016\/j.beha.2025.101637_bib39","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.beha.2025.101637_bib40","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1182\/blood.2022015478","article-title":"Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma","volume":"140","author":"Elsawy","year":"2022","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.beha.2025.101637_bib41","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1182\/blood.2023023447","article-title":"Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity","volume":"143","author":"Locke","year":"2024","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.beha.2025.101637_bib42","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1038\/s41591-023-02572-5","article-title":"Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial","volume":"29","author":"Houot","year":"2023","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.beha.2025.101637_bib43","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1158\/2643-3230.BCD-23-0112","article-title":"Product attributes of CAR T-cell therapy differentially associate with efficacy and toxicity in second-line large B-cell lymphoma (ZUMA-7)","volume":"5","author":"Filosto","year":"2024","journal-title":"Blood Cancer Discov"},{"issue":"21","key":"10.1016\/j.beha.2025.101637_bib44","first-page":"1790","article-title":"Dose-Adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the phase III intergroup trial alliance\/CALGB 50303","volume":"37","author":"Bartlett","year":"2019","journal-title":"J Clin Orthod"},{"key":"10.1016\/j.beha.2025.101637_bib45","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2024027347","article-title":"Three-year follow-up analysis of first-line axicabtagene ciloleucel in high-risk large B-cell lymphoma (ZUMA-12)","author":"Chavez","year":"2025","journal-title":"Blood J"},{"issue":"20","key":"10.1016\/j.beha.2025.101637_bib46","doi-asserted-by":"crossref","first-page":"6191","DOI":"10.1182\/bloodadvances.2023011203","article-title":"Outcomes of axicabtagene ciloleucel in PMBCL compare favorably with those in DLBCL: a GLA\/DRST registry study","volume":"7","author":"Schubert","year":"2023","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.beha.2025.101637_bib47","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1038\/s41375-024-02213-x","article-title":"Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE study","volume":"38","author":"Chiappella","year":"2024","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.beha.2025.101637_bib48","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.70091","article-title":"Outcomes of patients with relapsed or refractory primary mediastinal B\u2010cell lymphoma treated with anti\u2010CD19 CAR\u2010T cells: CARTHYM, a study from the French national DESCAR\u2010T registry","volume":"9","author":"Galtier","year":"2025","journal-title":"HemaSphere"},{"issue":"16_suppl","key":"10.1016\/j.beha.2025.101637_bib49","article-title":"A pilot study of axicabtagene ciloleucel (axi-cel) for relapsed\/refractory primary and secondary central nervous system lymphoma (PCNSL and SCNSL)","volume":"42","author":"Nayak","year":"2024","journal-title":"J Clin Orthod"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2025.101637_bib50","doi-asserted-by":"crossref","first-page":"12788","DOI":"10.1182\/blood-2022-157292","article-title":"Trial-in-Progress: amc 112: axicabtagene ciloleucel in relapsed or refractory HIV-associated aggressive B-cell non-hodgkin lymphoma (NCT05077527)","volume":"140","author":"Epstein-Peterson","year":"2022","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.beha.2025.101637_bib51","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1016\/j.clml.2024.01.011","article-title":"A comparison of 3-year follow-up of ZUMA-5 (axicabtagene ciloleucel) with SCHOLAR-5 in relapsed\/refractory follicular lymphoma","volume":"24","author":"Ghione","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"9","key":"10.1016\/j.beha.2025.101637_bib52","doi-asserted-by":"crossref","first-page":"885.e1","DOI":"10.1016\/j.jtct.2024.06.016","article-title":"Matching-Adjusted indirect comparisons of axicabtagene ciloleucel to mosunetuzumab for the treatment of relapsed\/refractory follicular lymphoma","volume":"30","author":"Ray","year":"2024","journal-title":"Transplant Cell Therapy"},{"issue":"8","key":"10.1016\/j.beha.2025.101637_bib53","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","article-title":"Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study","volume":"23","author":"Budde","year":"2022","journal-title":"Lancet Oncol"},{"issue":"S3","key":"10.1016\/j.beha.2025.101637_bib54","doi-asserted-by":"crossref","DOI":"10.1097\/01.HS9.0000971324.63506.62","article-title":"P1107: ZUMA-22: a phase 3, randomized controlled study of axicabtagene ciloleucel versus standard-of-care therapy in patients with relapsed or refractory follicular lymphoma","volume":"7","author":"Flinn","year":"2023","journal-title":"HemaSphere"},{"issue":"22","key":"10.1016\/j.beha.2025.101637_bib55","doi-asserted-by":"crossref","first-page":"5773","DOI":"10.1182\/bloodadvances.2020003121","article-title":"Durable ibrutinib responses in relapsed\/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis","volume":"4","author":"Noy","year":"2020","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.beha.2025.101637_bib56","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/blood.2023021243","article-title":"Three-year follow-up analysis of axicabtagene ciloleucel in relapsed\/refractory indolent non-Hodgkin lymphoma (ZUMA-5)","volume":"143","author":"Neelapu","year":"2024","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1016\/j.beha.2025.101637_bib57","article-title":"Axicabtagene ciloleucel (axi-cel) in combination with rituximab (Rtx) for the treatment (Tx) of refractory large B-cell lymphoma (R-LBCL): outcomes of the phase 2 ZUMA-14 study","volume":"40","author":"Strati","year":"2022","journal-title":"J Clin Orthod"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2025.101637_bib58","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-111523","article-title":"End of phase 1 results from zuma-6: axicabtagene ciloleucel (Axi-Cel) in combination with atezolizumab for the treatment of patients with refractory diffuse large B cell lymphoma","volume":"132","author":"Jacobson","year":"2018","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2025.101637_bib59","article-title":"Phase II trial of axicabagene ciloleucel and glofitamab as second-line therapy for patients with relapsed or refractory large B-cell lymphoma","volume":"144","author":"Kim","year":"2024","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2025.101637_bib60","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/s41591-023-02754-1","article-title":"Impact of tumor microenvironment on efficacy of anti-CD19 CAR T cell therapy or chemotherapy and transplant in large B cell lymphoma","volume":"30","author":"Locke","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.beha.2025.101637_bib61","article-title":"Tumor gene expression signatures associated with outcome in large B\u2212cell lymphoma treated with CD19-directed CAR T\u2212cell therapy (axicabtagene ciloleucel)","volume":"15","author":"Tian","year":"2025","journal-title":"Front Oncol"},{"issue":"8","key":"10.1016\/j.beha.2025.101637_bib62","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1182\/bloodadvances.2024012563","article-title":"Monocytes in leukapheresis products affect the outcome of CD19\u2013targeted CAR T-cell therapy in patients with lymphoma","volume":"8","author":"Carniti","year":"2024","journal-title":"Blood Adv"},{"issue":"24","key":"10.1016\/j.beha.2025.101637_bib63","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1182\/blood.2023021620","article-title":"Axicabtagene ciloleucel vs standard of care in second-line large B-cell lymphoma: outcomes by metabolic tumor volume","volume":"143","author":"Locke","year":"2024","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.beha.2025.101637_bib64","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","article-title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Schuster","year":"2021","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.beha.2025.101637_bib65","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009890","article-title":"Real-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: subgroup analyses from the CIBMTR registry","volume":"13","author":"Landsburg","year":"2025","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.beha.2025.101637_bib66","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/s41408-023-00889-5","article-title":"Comparison of tisagenlecleucel with conventional treatments for relapsed\/refractory diffuse large B-cell lymphomas: a retrospective external comparator study","volume":"13","author":"Park","year":"2023","journal-title":"Blood Cancer J"},{"issue":"8","key":"10.1016\/j.beha.2025.101637_bib67","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1182\/bloodadvances.2021006280","article-title":"Indirect comparison of tisagenlecleucel and historical treatments for relapsed\/refractory diffuse large B-cell lymphoma","volume":"6","author":"Maziarz","year":"2022","journal-title":"Blood Adv"},{"issue":"14","key":"10.1016\/j.beha.2025.101637_bib68","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1182\/bloodadvances.2019000151","article-title":"Tisagenlecleucel in relapsed\/refractory diffuse large B-cell lymphoma patients without measurable disease at infusion","volume":"3","author":"Bishop","year":"2019","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.beha.2025.101637_bib69","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1182\/bloodadvances.2019001026","article-title":"Patient-reported long-term quality of life after tisagenlecleucel in relapsed\/refractory diffuse large B-cell lymphoma","volume":"4","author":"Maziarz","year":"2020","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.beha.2025.101637_bib70","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa2116596","article-title":"Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma","volume":"386","author":"Bishop","year":"2022","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.beha.2025.101637_bib71","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1182\/bloodadvances.2022007779","article-title":"Safety and efficacy of tisagenlecleucel plus pembrolizumab in patients with r\/r DLBCL: phase 1b PORTIA study results","volume":"7","author":"Jaeger","year":"2023","journal-title":"Blood Adv"},{"issue":"15","key":"10.1016\/j.beha.2025.101637_bib72","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1182\/blood.2021014738","article-title":"Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1\/2 clinical trial","volume":"139","author":"Frigault","year":"2022","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2025.101637_bib73","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-148444","article-title":"Tisagenlecleucel demonstrates safety, efficacy and CNS trafficking in primary CNS lymphoma","volume":"138","author":"Frigault","year":"2021","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2025.101637_bib74","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial","volume":"28","author":"Fowler","year":"2022","journal-title":"Nat Med"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2025.101637_bib75","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-180936","article-title":"Clinical outcomes of patients with relapsed\/refractory follicular lymphoma treated with tisagenlecleucel: phase 2 elara 3-year follow-up","volume":"142","author":"Schuster","year":"2023","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.beha.2025.101637_bib76","doi-asserted-by":"crossref","first-page":"5835","DOI":"10.1182\/bloodadvances.2022008150","article-title":"Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma","volume":"6","author":"Salles","year":"2022","journal-title":"Blood Adv"},{"issue":"8","key":"10.1016\/j.beha.2025.101637_bib77","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1182\/blood.2023021306","article-title":"CAR T cells and time-limited ibrutinib as treatment for relapsed\/refractory mantle cell lymphoma: the phase 2 TARMAC study","volume":"143","author":"Minson","year":"2024","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.beha.2025.101637_bib78","doi-asserted-by":"crossref","first-page":"4657","DOI":"10.1182\/bloodadvances.2022007057","article-title":"Real-world characteristics of T-cell apheresis and clinical response to tisagenlecleucel in B-cell lymphoma","volume":"6","author":"Cuffel","year":"2022","journal-title":"Blood Adv"},{"issue":"17","key":"10.1016\/j.beha.2025.101637_bib79","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood.2023021567","article-title":"Durable response after tisagenlecleucel in adults with relapsed\/refractory follicular lymphoma: ELARA trial update","volume":"143","author":"Dreyling","year":"2024","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.beha.2025.101637_bib80","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.beha.2025.101637_bib81","first-page":"555","article-title":"Three-year follow-up of KTE-X19 in patients with relapsed\/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Orthod"},{"issue":"1","key":"10.1016\/j.beha.2025.101637_bib82","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1080\/10428194.2023.2268228","article-title":"Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed\/refractory mantle cell lymphoma","volume":"65","author":"Hess","year":"2024","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"10.1016\/j.beha.2025.101637_bib83","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000949","article-title":"Repeated infusions of brexucabtagene-autoleucel in relapsed\/refractory mantle cell lymphoma","volume":"7","author":"Aydilek","year":"2023","journal-title":"HemaSphere"},{"issue":"6","key":"10.1016\/j.beha.2025.101637_bib84","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1002\/hem3.87","article-title":"Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in the United Kingdom: a real\u2010world intention\u2010to\u2010treat analysis","volume":"8","author":"O'Reilly","year":"2024","journal-title":"HemaSphere"},{"issue":"11","key":"10.1016\/j.beha.2025.101637_bib85","first-page":"3745","article-title":"Brexucabtagene autoleucel in relapsed or refractory mantle cell lymphoma, intention-to-treat use in the DESCAR-T registry","volume":"109","author":"Herbaux","year":"2024","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.beha.2025.101637_bib86","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/bjh.19961","article-title":"Brexucabtagene autoleucel in\u2010vivo expansion and BTKi refractoriness have a negative influence on progression\u2010free survival in mantle cell lymphoma: results from CART \u2010 SIE study","volume":"206","author":"Stella","year":"2025","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.beha.2025.101637_bib87","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1182\/blood.2023020854","article-title":"Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001","volume":"143","author":"Abramson","year":"2024","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2025.101637_bib88","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1182\/bloodadvances.2020003503","article-title":"Effect of lisocabtagene maraleucel on HRQoL and symptom severity in relapsed\/refractory large B-cell lymphoma","volume":"5","author":"Patrick","year":"2021","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2025.101637_bib89","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2024-200204","article-title":"Five-year survival of patients (pts) from transcend NHL 001 (TRANSCEND) supports curative potential of lisocabtagene maraleucel (liso-cel) in relapsed or refractory (R\/R) large B-cell lymphoma (LBCL)","volume":"144","author":"Abramson","year":"2024","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.beha.2025.101637_bib90","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1182\/bloodadvances.2024014164","article-title":"Lisocabtagene maraleucel for relapsed\/refractory large B-cell lymphoma: a cell therapy consortium real-world analysis","volume":"9","author":"Riedell","year":"2025","journal-title":"Blood Adv"},{"issue":"8","key":"10.1016\/j.beha.2025.101637_bib91","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S1470-2045(22)00339-4","article-title":"Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study","volume":"23","author":"Sehgal","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.beha.2025.101637_bib92","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2024015262","article-title":"Lisocabtagene maraleucel for R\/R LBCL in patients not intended for HSCT: final results of the phase 2 PILOT study","author":"Sehgal","year":"2025","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.beha.2025.101637_bib93","first-page":"693","article-title":"Comparative efficacy of lisocabtagene maraleucel in the PILOT study versus second-line chemotherapy regimens in the real world","volume":"110","author":"Ghosh","year":"2024","journal-title":"Haematologica"},{"issue":"23","key":"10.1016\/j.beha.2025.101637_bib94","doi-asserted-by":"crossref","first-page":"5969","DOI":"10.1182\/bloodadvances.2022008106","article-title":"Health-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCL","volume":"6","author":"Abramson","year":"2022","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.beha.2025.101637_bib95","doi-asserted-by":"crossref","first-page":"857","DOI":"10.3324\/haematol.2023.283162","article-title":"Lisocabtagene maraleucel for second-line relapsed or refractory large B-cell lymphoma: patient-reported outcomes from the PILOT study","volume":"109","author":"Gordon","year":"2023","journal-title":"Haematol"},{"issue":"10343","key":"10.1016\/j.beha.2025.101637_bib96","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.beha.2025.101637_bib97","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood.2022018730","article-title":"Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study","volume":"141","author":"Abramson","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2025.101637_bib98","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2024-199813","volume":"144","author":"Stepan","year":"2024","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.beha.2025.101637_bib99","first-page":"1146","article-title":"Lisocabtagene maraleucel in relapsed\/refractory mantle cell lymphoma: primary analysis of the mantle cell lymphoma cohort from TRANSCEND NHL 001, a phase I multicenter seamless design study","volume":"42","author":"Wang","year":"2024","journal-title":"J Clin Orthod"},{"issue":"8","key":"10.1016\/j.beha.2025.101637_bib100","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1038\/s41591-024-02986-9","article-title":"Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study","volume":"30","author":"Morschhauser","year":"2024","journal-title":"Nat Med"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2025.101637_bib101","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-178786","article-title":"Matching-Adjusted indirect comparison (MAIC) of efficacy and safety of lisocabtagene maraleucel (liso-cel) and mosunetuzumab for the treatment (tx) of third line or later (3L+) relapsed or refractory (R\/R) follicular lymphoma (FL)","volume":"142","author":"Nastoupil","year":"2023","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2025.101637_bib102","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/s41591-022-01731-4","article-title":"Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial","volume":"28","author":"Neelapu","year":"2022","journal-title":"Nat Med"},{"issue":"20","key":"10.1016\/j.beha.2025.101637_bib103","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1182\/blood.2024027347","article-title":"Three-year follow-up analysis of first-line axicabtagene ciloleucel in high-risk large B-cell lymphoma (ZUMA-12)","volume":"145","author":"Chavez","year":"2025","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2025.101637_bib104","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.beha.2025.101637_bib105","doi-asserted-by":"crossref","DOI":"10.1038\/s41409-025-02551-z","article-title":"Feasibility of axicabtagene ciloleucel in the outpatient setting: primary analysis of prospective trial","author":"Dholaria","year":"2025","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.beha.2025.101637_bib106","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"10254","key":"10.1016\/j.beha.2025.101637_bib107","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.beha.2025.101637_bib108","first-page":"1146","article-title":"Lisocabtagene maraleucel in relapsed\/refractory mantle cell lymphoma: primary analysis of the mantle cell lymphoma cohort from TRANSCEND NHL 001, a phase I multicenter seamless design study","volume":"42","author":"Wang","year":"2024","journal-title":"J Clin Orthod"},{"issue":"23","key":"10.1016\/j.beha.2025.101637_bib109","doi-asserted-by":"crossref","first-page":"6114","DOI":"10.1182\/bloodadvances.2024013254","article-title":"OUTREACH: phase 2 study of lisocabtagene maraleucel as outpatient or inpatient treatment at community sites for R\/R LBCL","volume":"8","author":"Linhares","year":"2024","journal-title":"Blood Adv"},{"issue":"S2","key":"10.1016\/j.beha.2025.101637_bib110","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1002\/hon.3196_LBA4","article-title":"Transcend FL: phase 2 study results of lisocabtagene maraleucel (LISO\u2010CEL) in patients (pts) with relapsed\/refractory (R\/R) follicular lymphoma (FL)","volume":"41","author":"Morschhauser","year":"2023","journal-title":"Hematol Oncol"},{"issue":"8","key":"10.1016\/j.beha.2025.101637_bib111","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1038\/s41591-024-02986-9","article-title":"Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study","volume":"30","author":"Morschhauser","year":"2024","journal-title":"Nat Med"},{"issue":"24","key":"10.1016\/j.beha.2025.101637_bib112","doi-asserted-by":"crossref","first-page":"4889","DOI":"10.1002\/cam4.4820","article-title":"Phase 2 results of lisocabtagene maraleucel in Japanese patients with relapsed\/refractory aggressive B\u2010cell non\u2010Hodgkin lymphoma","volume":"11","author":"Makita","year":"2022","journal-title":"Cancer Med"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2025.101637_bib113","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2024-204264","article-title":"Rapcabtagene autoleucel (YTB323) in patients (pts) with relapsed\/refractory diffuse large B-cell lymphoma (R\/R DLBCL): phase II trial clinical update","volume":"144","author":"Riedell","year":"2024","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2025.101637_bib114","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-189196","article-title":"ALLO-647 for lymphodepletion in the allogeneic CAR T setting: safety experience with ALLO-501\/501a in patients (pts) with relapsed\/refractory (r\/r) large B-cell and follicular lymphomas","volume":"142","author":"Locke","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2025.101637_bib115","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2024-208461","article-title":"A phase 1, multicenter, open-label study of UB-VV111 in combination with rapamycin in relapsed\/refractory CD19+ B-cell malignancies","volume":"144","author":"Garcia","year":"2024","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2025.101637_bib116","doi-asserted-by":"crossref","DOI":"10.1002\/jha2.70015","article-title":"Clinical impact of CD19 expression assessed by quantitative PCR in lymphoma patients undergoing CAR\u2010T therapy","volume":"6","author":"Hernani","year":"2025","journal-title":"eJHaem"},{"issue":"11","key":"10.1016\/j.beha.2025.101637_bib117","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.3390\/cancers15113058","article-title":"Clinical impact of single nucleotide polymorphism in CD-19 on treatment outcome in FMC63-CAR-T cell therapy","volume":"15","author":"Seipel","year":"2023","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.beha.2025.101637_bib118","first-page":"1026","article-title":"CD20-specific chimeric antigen receptor-expressing T cells as salvage therapy in rituximab-refractory\/relapsed B-cell non-Hodgkin lymphoma","volume":"24","author":"Cheng","year":"2022","journal-title":"Cytopathology (Oxf)"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2025.101637_bib119","article-title":"Two-year follow-up results of C-CAR066, a novel anti-CD20 chimeric antigen receptor cell therapy (CAR-T) in relapsed or refractory (r\/r) large B-cell lymphoma (LBCL) patients after failure of CD19 CAR-T therapy","volume":"142","author":"Li","year":"2023","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.beha.2025.101637_bib120","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1002\/ajh.27488","article-title":"C\u2010 CAR066 , a novel fully human anti\u2010 CD20 CAR \u2010T therapy for relapsed or refractory large B\u2010cell lymphoma after failure of anti\u2010 CD19 CAR \u2010T therapy: A phase I clinical study","volume":"99","author":"Li","year":"2024","journal-title":"Am J Hematol"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2025.101637_bib121","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2024-205207","article-title":"Tandem CD19\/20 CAR-T showed durable efficacy in patients with relapsed\/refractory B-cell lymphoma: interim results from a multicenter phase I\/II trial","volume":"144","author":"Wei","year":"2024","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2025.101637_bib122","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1158\/2159-8290.CD-22-0964","article-title":"CD19\/CD20 bispecific chimeric antigen receptor (CAR) in naive\/memory T cells for the treatment of relapsed or refractory non-hodgkin lymphoma","volume":"13","author":"Larson","year":"2023","journal-title":"Cancer Discov"},{"issue":"14","key":"10.1016\/j.beha.2025.101637_bib123","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1182\/blood.2024026401","article-title":"A phase 1 trial of prizloncabtagene autoleucel, a CD19\/CD20 CAR T-cell therapy for relapsed\/refractory B-cell non-Hodgkin lymphoma","volume":"145","author":"Yu","year":"2025","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2025.101637_bib124","article-title":"CD22-Directed CAR T-cell therapy achieves complete remission in CD19-directed CAR T-cell refractory follicular and mantle cell lymphoma","volume":"144","author":"Kramer","year":"2024","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2025.101637_bib125","doi-asserted-by":"crossref","first-page":"S388","DOI":"10.1016\/j.jtct.2025.01.599","article-title":"CD22-Directed CAR T-cell therapy achieves complete remission in CD19-directed CAR T-cell refractory follicular and mantle cell lymphoma with superior safety and absence of neurotoxicity","volume":"31","author":"Srinagesh","year":"2025","journal-title":"Transplant Cell Therapy"},{"issue":"10450","key":"10.1016\/j.beha.2025.101637_bib126","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0140-6736(24)00746-3","article-title":"CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study","volume":"404","author":"Frank","year":"2024","journal-title":"Lancet"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2025.101637_bib127","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2024-210123","article-title":"Preliminary safety and tolerability of CD19x22 CAR-T cell therapy in adolescent and adult patients with relapsed or refractory B-cell non-hodgkin lymphoma","volume":"144","author":"Kamdar","year":"2024","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2025.101637_bib128","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2024-198416","article-title":"Favorable safety profile and durable responses to pmb-CT01 (BAFFR-CAR T cell) therapy in patients with B-cell lymphomas ineligible for or who failed CD19-targeted therapy, including CD19-negative disease","volume":"144","author":"Del Real","year":"2024","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.beha.2025.101637_bib129","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1182\/blood.2024024104","article-title":"Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37+ lymphoid malignancies","volume":"144","author":"Frigault","year":"2024","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.beha.2025.101637_bib130","doi-asserted-by":"crossref","first-page":"4418","DOI":"10.1182\/bloodadvances.2022007059","article-title":"CD38 as a pan-hematologic target for chimeric antigen receptor T cells","volume":"7","author":"Glisovic-Aplenc","year":"2023","journal-title":"Blood Adv"},{"issue":"14","key":"10.1016\/j.beha.2025.101637_bib131","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1182\/blood.2021014760","article-title":"ROR1: an orphan becomes apparent","volume":"140","author":"Kipps","year":"2022","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.beha.2025.101637_bib132","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2010-05-283309","article-title":"The B-cell tumor\u2013associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor","volume":"116","author":"Hudecek","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2025.101637_bib133","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/s41420-024-02239-1","article-title":"Therapeutic advances in the targeting of ROR1 in hematological cancers","volume":"10","author":"Tigu","year":"2024","journal-title":"Cell Death Discov"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2025.101637_bib134","article-title":"A phase 1\/2 study of a ROR1-targeting CAR T cell therapy (ONCT-808) in adult patients with relapsed\/refractory (R\/R) aggressive B cell lymphomas (BCL)","volume":"144","author":"Wang","year":"2024","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2025.101637_bib135","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1080\/10428194.2023.2289854","article-title":"Comparative efficacy and safety of tisagenlecleucel and axicabtagene ciloleucel among adults with r\/r follicular lymphoma","volume":"65","author":"Dickinson","year":"2024","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1016\/j.beha.2025.101637_bib136","doi-asserted-by":"crossref","first-page":"584.e1","DOI":"10.1016\/j.jtct.2024.01.074","article-title":"Axicabtagene ciloleucel versus tisagenlecleucel for relapsed or refractory large B cell lymphoma: a systematic review and meta-analysis","volume":"30","author":"Gagelmann","year":"2024","journal-title":"Transplant Cell Therapy"},{"issue":"1","key":"10.1016\/j.beha.2025.101637_bib137","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3324\/haematol.2022.280805","article-title":"Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma","volume":"108","author":"Kwon","year":"2022","journal-title":"Haematol"},{"issue":"3","key":"10.1016\/j.beha.2025.101637_bib138","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3390\/curroncol32030173","article-title":"Enhancing CAR-T efficacy in large B-cell lymphoma with radiation bridging therapy: a real-world single-center experience","volume":"32","author":"Laverdure","year":"2025","journal-title":"Curr Oncol"},{"issue":"10","key":"10.1016\/j.beha.2025.101637_bib139","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1038\/s41591-022-01969-y","article-title":"A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma","volume":"28","author":"Bachy","year":"2022","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.beha.2025.101637_bib140","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1158\/2643-3230.BCD-24-0052","article-title":"A multicenter real-life prospective study of axicabtagene ciloleucel versus tisagenlecleucel toxicity and outcomes in large B-cell lymphomas","volume":"5","author":"Stella","year":"2024","journal-title":"Blood Cancer Discov"},{"issue":"4","key":"10.1016\/j.beha.2025.101637_bib141","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1080\/10428194.2021.2010069","article-title":"Comparative efficacy of tisagenlecleucel and lisocabtagene maraleucel among adults with relapsed\/refractory large B-cell lymphomas: an indirect treatment comparison","volume":"63","author":"Schuster","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.beha.2025.101637_bib142","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s13045-021-01144-9","article-title":"Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphoma","volume":"14","author":"Maloney","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10.1016\/j.beha.2025.101637_bib143","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s40164-022-00268-z","article-title":"Matching-adjusted indirect treatment comparison of chimeric antigen receptor T-cell therapies for third-line or later treatment of relapsed or refractory large B-cell lymphoma: lisocabtagene maraleucel versus tisagenlecleucel","volume":"11","author":"Cartron","year":"2022","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.beha.2025.101637_bib144","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2024.287010","article-title":"Real-world comparison of lisocabtagene maraleucel and axicabtagene ciloleucel in large B-cell lymphoma: an inverse probability of treatment weighting analysis with 3-year follow up","author":"Portuguese","year":"2025","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.beha.2025.101637_bib145","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1182\/bloodadvances.2024012992","article-title":"A real-world comparison of commercial-use axicabtagene ciloleucel and lisocabtagene maraleucel in large B-cell lymphoma","volume":"9","author":"Looka","year":"2025","journal-title":"Blood Adv"},{"issue":"9","key":"10.1016\/j.beha.2025.101637_bib146","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1182\/blood.2021013289","article-title":"Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission","volume":"139","author":"Shadman","year":"2022","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2025.101637_bib147","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1007\/s12185-024-03888-9","article-title":"Outcomes of allogeneic SCT versus tisagenlecleucel in patients with R\/R LBCL and poor prognostic factors","volume":"121","author":"Hayashino","year":"2025","journal-title":"Int J Hematol"},{"issue":"3","key":"10.1016\/j.beha.2025.101637_bib148","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1158\/2643-3230.BCD-24-0178","article-title":"Brexucabtagene autoleucel versus allogeneic hematopoietic cell transplantation in relapsed and refractory mantle cell lymphoma","volume":"6","author":"Liebers","year":"2025","journal-title":"Blood Cancer Discov"},{"issue":"S3","key":"10.1016\/j.beha.2025.101637_bib149","doi-asserted-by":"crossref","DOI":"10.1097\/01.HS9.0000976104.50042.ff","article-title":"PB2346: ZUMA-24: a phase 2, open-label, multicenter study of axicabtagene ciloleucel in patients with relapsed\/refractory large B-cell lymphoma given with corticosteroids in the outpatient setting","volume":"7","author":"Leslie","year":"2023","journal-title":"HemaSphere"},{"issue":"8","key":"10.1016\/j.beha.2025.101637_bib150","doi-asserted-by":"crossref","first-page":"e730","DOI":"10.1016\/j.clml.2022.04.012","article-title":"Outcomes of tisagenlecleucel in lymphoma patients with predominant management in an ambulatory setting","volume":"22","author":"Nasta","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"17","key":"10.1016\/j.beha.2025.101637_bib151","doi-asserted-by":"crossref","first-page":"4765","DOI":"10.1182\/bloodadvances.2022008937","article-title":"Chimeric antigen receptor T-cell therapy yields similar outcomes in patients with and without cytokine release syndrome","volume":"7","author":"Bhaskar","year":"2023","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.beha.2025.101637_bib152","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/s41409-023-02169-z","article-title":"Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroids","volume":"59","author":"Oluwole","year":"2024","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"10.1016\/j.beha.2025.101637_bib153","doi-asserted-by":"crossref","first-page":"573.e1","DOI":"10.1016\/j.jtct.2023.06.018","article-title":"Negative prognostic impact of high-dose or long-term corticosteroid use in patients with relapsed or refractory B-cell lymphoma who received tisagenlecleucel","volume":"29","author":"Terao","year":"2023","journal-title":"Transplant Cell Therapy"},{"issue":"2","key":"10.1016\/j.beha.2025.101637_bib154","doi-asserted-by":"crossref","first-page":"S118","DOI":"10.1016\/j.jtct.2024.01.005","article-title":"Phase I study of duvelisib study for cytokine release syndrome prophylaxis in patients receiving chimeric antigen receptor T cell treatment for non-hodgkin lymphoma","volume":"30","author":"Slade","year":"2024","journal-title":"Transplant Cell Therapy"},{"issue":"20","key":"10.1016\/j.beha.2025.101637_bib155","doi-asserted-by":"crossref","first-page":"5346","DOI":"10.1182\/bloodadvances.2023012549","article-title":"Optimizing the post-CAR T monitoring period in recipients of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel","volume":"8","author":"Ahmed","year":"2024","journal-title":"Blood Adv"},{"issue":"8","key":"10.1016\/j.beha.2025.101637_bib156","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000907","article-title":"Inferior outcomes of EU versus US patients treated with CD19 CAR-T for relapsed\/refractory large B-cell lymphoma: association with differences in tumor burden, systemic inflammation, bridging therapy utilization, and CAR-T product use","volume":"7","author":"B\u00fccklein","year":"2023","journal-title":"HemaSphere"}],"container-title":["Best Practice &amp; Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692625000428?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692625000428?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T20:39:38Z","timestamp":1762547978000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692625000428"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":156,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S1521692625000428"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2025.101637","relation":{},"ISSN":["1521-6926"],"issn-type":[{"type":"print","value":"1521-6926"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adoptive cellular therapies in non-Hodgkin lymphomas","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2025.101637","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101637"}}